Dr. Chhatwal is the Director of the MGH Institute for Technology Assessment (ITA) and an Associate Professor at Harvard Medical School. His research is centered in decision science, data analytics, outcomes research and health economics. He has over 10 years of experience in developing decision-analytic models to evaluate disease outcomes. He currently leads research in multiple disease areas including COVID-19, hepatitis C, liver cancer, liver transplantation, nonalcoholic fatty liver disease (NAFLD), and opioid and alcohol use disorder.
Dr. Chhatwal is the Principal Investigator of a grant from the National Science Foundation that supports development of advanced data-analytic models to evaluate screening and treatment policies for hepatitis C in the United States, and a grant from the American Cancer Society to identify cost-effectiveness personalized surveillance strategy for hepatocellular carcinoma. Recently, he was awarded AASLD Innovation Fund from the American Association for the Study of Liver Diseases (AASLD) to develop interactive tools to address the rising disease burden of NAFLD.
In collaboration with the World Health Organization, Dr. Chhatwal developed an online, interactive tool -- Hep C Calculator -- that evaluates the cost-effectiveness of hepatitis C treatment in 28+ countries. Hep C Calculator allows users to interactively enter local cost data of a country and see the cost-effectiveness results in real-time.
His research on hepatitis C modeling has made a direct impact on defining hepatitis C screening and treatment policies, in the United States as well as elsewhere. His work on the cost and impact new hepatitis C drugs has been featured by The Wall Street Journal, Forbes, NPR, and CNBC. In addition, Dr. Chhatwal has conducted research on breast cancer diagnosis, which showed how machine learning and operations research methods can improve biopsy decision-making after mammography exams. This work won multiple awards including a best junior faculty paper and best student paper from the Institute for Operations Research and Management Science.
His research interests also include advancement of decision-analytic methods for medical decision-making. Dr. Chhatwal regularly teaches cost-effectiveness and decision modeling workshops at the annual meetings of the Society for Medical Decision Making and International Society for Pharmacoeconomics and Outcomes Research. He serves as a cost-effectiveness and decision analysis editor to the journal Clinical Gastroenterology and Hepatology, and is also an editorial board member of Medical Decision Making.
Prior to joining the ITA, Dr. Chhatwal worked as a health economist for Merck Research Laboratories and was a faculty member at the University of Pittsburgh Graduate School of Public Health and MD Anderson Cancer Center. He received a Bachelor's Degree in Industrial Engineering from Thapar Institute of Engineering and Technology, India in 2001. He then pursued a Master's Degree in Industrial Engineering at Iowa State University in 2004, and a PhD in Industrial Engineering, focusing on operations research, at the University of Wisconsin-Madison in 2008. For his PhD thesis on breast cancer diagnosis, he won 2nd place prize in George Dantzig dissertation award, a prestigious award for the best dissertation in any area of operations research and management science that is innovative and relevant to practice.
Selected media coverage:
Podcast 5/6/2022: Case Confirmed: A Public Health Podcast Series Featuring Simulating the Future of COVID-19: A Conversation with Dr. Jagpreet Chhatwal
Boston Globe 1/21/2022: What can Google search trends for COVID-19 symptoms tell us about the direction of the pandemic?
U.S. News & World Report 12/24/2021: Heavier Drinking During Pandemic Means More Liver Disease to Come
Boston Globe 12/24/2021: One model projects a sobering outlook for rising COVID-19 cases in the US and Mass. as Omicron surges
Boston Herald 8/28/2021: Football games with reduced capacity did not cause uptick in coronavirus cases, study finds
U.S. News & World Report 8/19/2021: Limited-Seating Football Games Don't Seem to Spread COVID: Study
Boston Business Journal 8/24/2021: MGH study says football games haven't been superspreader events
Newsweek 8/16/2021: When Will the Delta Variant Peak? 'The Answer Is Within Our Control'
National Geographic 8/6/2021: How will the pandemic end? The science of past outbreaks offers clues.
WBUR 8/2/2021: Provincetown Becomes Test Case For Vaccines And Delta Variant
Newsweek 7/15/2021: As U.S. COVID Cases Rise, Deaths Could Hit Some States Harder Than Others
Voice of America 4/13/2021: Computerized Map Can Predict Next COVID-19 Outbreak
Washington Post 3/12/2021: COVID-19 deaths falling but Americans ‘must remain vigilant’
Politifact: Will Tampa’s Super Bowl be a super spreader? Experts worry about what NFL can’t control
Newsweek: One in 50 Americans Has COVID in Some Areas—Before New Variants Have Taken Hold
WBUR: Mass. General Hospital Builds COVID-19 Simulator To Help Predict Impact of Policy Decisions
Boston Globe: Limiting opioid prescriptions will do little to reduce overdose deaths, study says
Medscape: Countries Use Novel Strategies to Tackle Price of HCV Drugs
Medpage Today: Preemptive DAAs for HCV+ Donor Livers Found Cost Effective
Gastroenterology & Endoscopy News: In Decompensated Patients With High MELD Scores, HCV Best Treated After Transplant
The Economic Times: How beneficial are generic hepatitis C drugs available in India?
Stat News: Generic hepatitis C meds really are very cost effective, study says
WBUR: As Cancer Drugs' Prices Skyrocket, Experts Worry About Burden On Patients, Health Systems
WBUR: From The War On Cancer To The Moonshot: 'What's Different Now Is Everything'
Stat: High prices for some leukemia drugs will make them less cost-effective
Marketplace: Cutting prison hepatitis C rates: costly, but worth it?
WSJ: Hepatitis C Drugs are Cost Effective, but Affordability is Another Matter
Forbes: Critical Reports Mount On Hepatitis C Pill Costs
CBS News: Hepatitis C could be a rare disease in 20 years
The Washington Post: Cancer drugs aren't just really expensive; they're a bad value
The ASCO Post: Study Finds Current Prices of Hematologic Cancer Drugs Are Not Justified
In: Med Decis Making, vol. 43, no. 1, pp. 68–77, 2023, ISSN: 1552-681X.
In: Gynecol Oncol Rep, vol. 44, no. Suppl 1, pp. 101101, 2022, ISSN: 2352-5789.
In: Gynecol Oncol, vol. 169, pp. 113–117, 2022, ISSN: 1095-6859.
In: Am J Gastroenterol, vol. 117, no. 11, pp. 1834–1844, 2022, ISSN: 1572-0241.
In: Hepatol Commun, 2022, ISSN: 2471-254X.
In: Journal of hepatology, vol. 77, iss. 1, pp. 55-62, 2022, ISSN: 1600-0641.
In: Hepatology (Baltimore, Md.), vol. 75, iss. 6, pp. 1480-1490, 2022, ISSN: 1527-3350.
COVID-19 Health Economics: Looking Back and Scoping the Future Journal Article
In: Value Health, vol. 25, no. 5, pp. 695-696, 2022, ISSN: 1524-4733.
2022, ISSN: 1524-4733.
In: Proc Natl Acad Sci U S A, vol. 119, no. 15, pp. e2113561119, 2022, ISSN: 1091-6490.